Tirapazamine: A novel agent targeting hypoxic tumor cells

Expert Opinion on Investigational Drugs

Volumn 18, Issue 1, 2009, Pages 77-87

  Reddy, Srini B ^a   Williamson, Stephen K ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Cervical cancer; Cisplatin; Head and neck cancer; Hypoxic mammalian cells; Lung cancer; Radiation therapy; SR 4233; Tirapazamine; Tumor hypoxia

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUOROURACIL; MELPHALAN; METRONIDAZOLE; MITOMYCIN C; NAVELBINE; NITROFURAL; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; TIRAPAZAMINE;

ABDOMINAL CRAMP; ANEMIA; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DERMATITIS; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG SAFETY; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; GRANULOCYTOPENIA; HEAD AND NECK CANCER; HEARING IMPAIRMENT; HEARING LOSS; HEART MUSCLE ISCHEMIA; HUMAN; HYPOXIA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MELANOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCLE CRAMP; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; OTOTOXICITY; PERIPHERAL NEUROPATHY; RASH; REVIEW; RHABDOMYOSARCOMA; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TINNITUS; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR CELL; UNCONSCIOUSNESS; UTERINE CERVIX CANCER; VISUAL DISORDER; VOMITING; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; TREATMENT OUTCOME; TRIAZINES;

EID: 67649380881     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780802567250     Document Type: Review

References (45)

1. Brown JM. The hypoxic cell: a target for selective cancer therapy. Eighteenth Bruce F Cain Memorial Award lecture. Cancer Res 1999;59(23):5863-5870
2. Gandara DR, Lara PN Jr, Goldberg Z, et al. Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia. Semin Oncol 2002;29(1 Suppl 4):102-109 • Important review of preclinical and early clinical data. (Pubitemid 34226525)
3. Weitman S, Mangold G, Marty J, et al. Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft. Cancer Chemother Pharmacol 1999;43(5):402-408 (Pubitemid 29120251)
4. Zeman EM, Brown JM, Lemmon MJ, et al. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol 1986;12(7):1239-1242 (Pubitemid 16055893)
5. Delahoussaye YM, Evans JW, Brown JM. Metabolism of tirapazamine by multiple reductases in the nucleus. Biochem Pharmacol 2001;62(9):1201-1209 (Pubitemid 33055624)
6. Rauth AM, Mohindra JK, Tannock IF. Activity of mitomycin C for aerobic and hypoxic cells in vitro and in vivo Cancer Res 1983;43(9):4154-4158
7. Mohindra JK, Rauth AM. Increased cell killing by metronidazole and nitrofurazone of hypoxic compared to aerobic mammalian cells. Cancer Res 1976;36(3):930-936
8. Brown JM, Lemmon MJ. Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation. Int J Radiat Oncol 1991;20(3):457-461
9. Holden SA, Teicher BA, Ara G, et al. Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma. J Natl Cancer Inst 1992;84(3):187-193
10. Dorie MJ, Brown JM. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 1993;53(19):4633-4636 (Pubitemid 23304391)
11. Treat J, Johnson E, Langer C, et al. Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: a Phase II study. J Clin Oncol 1998;16(11):3524-3527 • Phase II evaluation of TPZ with cisplatin in NSCLC, part of the basis for subsequent Phase III trials. (Pubitemid 28506763)
12. von Pawel J, von Roemeling R, Gatzemeier U, et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors. J Clin Oncol 2000;18(6):1351-1359 •• Phase III trial demonstrating survival advantage of adding TPZ to cisplatin over cisplatin alone in advanced NSCLC.
13. Lee DJ, Trotti A, Spencer S et al. Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a Phase II study. Int J Radiat Oncol Biol Phys 1998;42(4):811-815 • Phase II trial in head and neck cancer. (Pubitemid 28559423)
14. Shulman LN, Buswell L, Riese N, et al. Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors. Int J Radiat Oncol Biol Phys 1999;44(2):349-353 (Pubitemid 29205033)
15. Doherty N, Hancock SL, Kaye S, et al. Muscle cramping in Phase I clinical trials of tirapazamine (SR 4233) with and without radiation. Int J Radiat Oncol Biol Phys 1994;29(2):379-382 (Pubitemid 24166550)
16. Senan S, Rampling R, Graham MA, et al. Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeks. Clin Cancer Res 1997;3(1):31-38 (Pubitemid 27079441)
17. Bedikian AY, Legha SS, Eton O, et al. Phase II trial of tirapazamine combined with cisplatin in chemotherapy of advanced malignant melanoma. Ann Oncol 1997;8(4):363-367 • Phase II trial in melanoma. (Pubitemid 27230977)
18. Rischin D, Peters L, Fisher R, et al. Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized Phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol 2005;23(1):79-87 • Randomized Phase II trial in head and neck cancer, supporting the use of combined TPZ/cisplatin and radiation compared with cisplatin and radiation in a Phase III trial. (Pubitemid 41702625)
19. Maluf FC, Leiser AL, Aghajanian C, et al. Phase II study of tirapazamine plus cisplatin in patients with advanced or recurrent cervical cancer. Int J Gynecol Cancer 2006;16(3):1165-1171 (Pubitemid 43886741)
20. Covens A, Blessing J, Bender D, et al. A Phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2006;100(3):586-590 (Pubitemid 43250628)
21. Miller VA, Ng KK, Grant SC, et al. Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 1997;8(12):1269-1271 (Pubitemid 28164084)
22. Shepherd F, Koschel G, von Pawl J, Gatzmeier U. Comparition of Tirazone (Tirapazamine) and cisplatin vs. etoposide and cisplatin in advanced non-small cell lung cancer(NSCLC): Final results of international Phase III CATAPULT II Trial [abstract]. Lung Cancer 2000;29(1 Suppl 1):S28 • Report of negative Phase III comparative trial in NSCLC in which the drug was not demonstrated to be able to be substituted for etoposide in the etoposide/cisplatin combination treatment regimen.
23. Williamson SK, Crowley JJ, Lara PN Jr, et al. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. J Clin Oncol 2005;23(36):9097-9104 •• Report of negative Phase III trial in NSCLC in which the drug did not demonstrate any improvement in survival by adding it to the regimen of paclitaxel/carboplatin combination. (Pubitemid 46260164)
24. Rischin D, Peters L, O'Sullivan B, et al. Phase III study of tirapazamine, cisplatin and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck [abstract LBA6008]. J Clin Oncol 2008;26(Suppl) •• Report of the only completed Phase III trial in head and neck cancer - no improvement in survival when TPZ is added to cisplatin and radiation therapy.
25. Smith HO, Jiang CS, Weiss GR, et al. Tirapazamine plus cisplatin in advanced or recurrent carcinoma of the uterine cervix: a Southwest Oncology Group study. Int J Gynecol Cancer 2006;16(1):298-305
26. Del Rowe J, Scott C, Werner-Wasik M, et al. Single-arm, open-label Phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme. J Clin Oncol 2000;18(6):1254-1259 (Pubitemid 30159843)
27. Mack PC, Redman MW, Chansky K, et al. Low osteopontin plasma levels are associated with superior outcomes following platinum-based chemotherapy in advanced non-small cell lung cancer patients: Southwest Oncology Group Trial S0003. J Clin Oncol 2008;26(29):4771-4776
28. Peters LJ, Rischin D, Fisher R, et al. Identification and therapeutic targeting of hypoxia in H & N cancer. Thirteenth International Congress of Radiation Research; 8 - 12 July 2007; San Francisco, CA; 2007. p. PS 1042
29. Durand RE, Olive PL. Physiologic and cytotoxic effects of tirapazamine in tumor-bearing mice. Radiat Oncol Investig 1997;5(5):213-219 (Pubitemid 27479449)
30. Hicks KO, Fleming Y, Siim BG, et al. Extravascular diffusion of tirapazamine: effect of metabolic consumption assessed using the multicellular layer model. Int J Radiat Oncol Biol Phys 1998;42(3):641-649 (Pubitemid 28501116)
31. Hicks KO, Pruijn FB, Secomb TW, et al. Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs. J Natl Cancer Inst 2006;98(16):1118-1128 (Pubitemid 44288786)
32. Hicks KO, Siim BG, Pruijn FB, Wilson WR. Oxygen dependence of the metabolic activation and cytotoxicity of tirapazamine: implications for extravascular transport and activity in tumors. Radiat Res 2004;161(6):656-666 (Pubitemid 39149574)
33. Kyle AH, Minchinton AI. Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model. Cancer Chemother Pharmacol 1999;43(3):213-220 (Pubitemid 29042489)
34. Bhattacharya A, Toth K, Durrani FA, et al. Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts. Neoplasia (New York, NY) 2008;10(8):857-865
35. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004;10(8):858-864 (Pubitemid 39070860)
36. Lee AE, Wilson WR. Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice. Toxicol Appl Pharmacol 2000;163(1):50-59 (Pubitemid 30111976)
37. Parmar K, Mauch P, Vergilio JA, et al. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci USA 2007;104(13):5431-5436 (Pubitemid 47175697)
38. De Jaeger K, Merlo FM, Kavanagh MC, et al. Heterogeneity of tumor oxygenation: relationship to tumor necrosis, tumor size, and metastasis. Int J Radiat Oncol 1998;42(4):717-721 (Pubitemid 28559404)
39. Brizel DM, Dodge RK, Clough RW, Dewhirst MW. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999;53(2):113-117
40. Fyles AW, Milosevic M, Pintilie M, Hill RP. Cervix cancer oxygenation measured following external radiation therapy. Int J Radiat Oncol Biol Phys 1998;42(4):751-753 (Pubitemid 28559411)
41. Nordsmark M, Overgaard J. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol 2000;57(1):39-43 (Pubitemid 30734321)
42. Johnson CA, Kilpatrick D, von Roemeling R, et al. Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumors. J Clin Oncol 1997;15(2):773-780 (Pubitemid 27074248)
43. Aghajanian C, Brown C, O'Flaherty C, et al. Phase I study of tirapazamine and cisplatin in patients with recurrent cervical cancer. Gynecol Oncol 1997;67(2):127-130 (Pubitemid 27500406)
44. Craighead PS, Pearcey R, Stuart G. A Phase I/II evaluation of tirapazamine administered intravenously concurrent with cisplatin and radiotherapy in women with locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 2000;48(3):791-795 (Pubitemid 30742653)
45. Le QT, McCoy J, Williamson S, et al. Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004):a Southwest Oncology Group study. Clin Cancer Res 2004;10(16):5418-5424